Market revenue in 2024 | USD 20.3 million |
Market revenue in 2030 | USD 16.7 million |
Growth rate | -3.6% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 58.13% in 2024. Horizon Databook has segmented the UAE anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of related conditions and the presence of a strong healthcare infrastructure are anticipated to drive the market. An article published in 2018 suggested that AMD is a rare condition in Dubai and patients mostly prefer public healthcare centers to seek treatment.
The government of UAE is advancing healthcare infrastructure to bridge the gap between healthcare facilities and increasing patient demands, for providing treatment to patients. In 2014, the government passed a bill, according to which, healthcare insurance is mandatory for UAE citizens.
In September 2019, Emirates Link Maltauro (ELM) granted the construction contract to Spain-based eye clinic, Barraquer Eye Hospital, to develop an eye care hospital in line with Vision 2021. This significant development may help address the unmet needs of patients and propel the market.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into UAE anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account